Therapeutic Category
- Antineoplastic Agent, RET Kinase Inhibitor
- Antineoplastic Agent, Tyrosine Kinase Inhibitor
Medication Safety Issues
Sound-alike/look-alike issues:
Pralsetinib may be confused with pazopanib, pemigatinib, pexidartinib, ponatinib, pralatrexate, ripretinib, selpercatinib.
High alert medication:
The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).
